Literature DB >> 1774294

Lyme disease assay which detects killed Borrelia burgdorferi.

S M Callister1, R F Schell, S D Lovrich.   

Abstract

We developed an in vitro assay showing that Borrelia burgdorferi organisms were killed by serum from patients with Lyme disease. Twenty of 20 Lyme disease serum samples caused B. burgdorferi killing in a range of 36 to 99% compared with the mean number of viable spirochetes when sera from 10 healthy individuals were used. The percentage of killing of B. burgdorferi increased with convalescent serum from patients with early Lyme disease. The borreliacidal activity was detectable in some sera diluted 640-fold and was abrogated after treatment with anti-human immunoglobulin G. In contrast, pooled or individual normal human serum did not cause a decrease in the number of viable B. burgdorferi. Borreliacidal activity was also not detected in sera from patients with relapsing fever, rocky mountain spotted fever, syphilis, mononucleosis, rheumatoid factor, or DNA antibodies. Our results show that borreliacidal activity can be used as a specific serodiagnostic test for detecting Lyme disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1774294      PMCID: PMC270208          DOI: 10.1128/jcm.29.9.1773-1776.1991

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

Review 1.  PRESENT DAY SERODIAGNOSIS OF SYPHILIS. A REVIEW OF SOME OF THE RECENT LITERATURE.

Authors:  L NICHOLAS; H BEERMAN
Journal:  Am J Med Sci       Date:  1965-04       Impact factor: 2.378

2.  Diagnosing Lyme disease: the contribution of serologic testing.

Authors:  J Duffy; L E Mertz; G H Wobig; J A Katzmann
Journal:  Mayo Clin Proc       Date:  1988-11       Impact factor: 7.616

3.  Lyme disease spirochetes and ixodid tick spirochetes share a common surface antigenic determinant defined by a monoclonal antibody.

Authors:  A G Barbour; S L Tessier; W J Todd
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

4.  Antibody response in Lyme disease: evaluation of diagnostic tests.

Authors:  J E Craft; R L Grodzicki; A C Steere
Journal:  J Infect Dis       Date:  1984-05       Impact factor: 5.226

5.  The spirochetal etiology of Lyme disease.

Authors:  A C Steere; R L Grodzicki; A N Kornblatt; J E Craft; A G Barbour; W Burgdorfer; G P Schmid; E Johnson; S E Malawista
Journal:  N Engl J Med       Date:  1983-03-31       Impact factor: 91.245

6.  The early clinical manifestations of Lyme disease.

Authors:  A C Steere; N H Bartenhagen; J E Craft; G J Hutchinson; J H Newman; D W Rahn; L H Sigal; P N Spieler; K S Stenn; S E Malawista
Journal:  Ann Intern Med       Date:  1983-07       Impact factor: 25.391

7.  Lyme disease-a tick-borne spirochetosis?

Authors:  W Burgdorfer; A G Barbour; S F Hayes; J L Benach; E Grunwaldt; J P Davis
Journal:  Science       Date:  1982-06-18       Impact factor: 47.728

8.  Cross-reactivity of nonspecific treponemal antibody in serologic tests for Lyme disease.

Authors:  L A Magnarelli; J N Miller; J F Anderson; G R Riviere
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

9.  Effects of bovine serum albumin on the ability of Barbour-Stoenner-Kelly medium to detect Borrelia burgdorferi.

Authors:  S M Callister; K L Case; W A Agger; R F Schell; R C Johnson; J L Ellingson
Journal:  J Clin Microbiol       Date:  1990-02       Impact factor: 5.948

10.  Role of immunoglobulin G in killing of Borrelia burgdorferi by the classical complement pathway.

Authors:  S K Kochi; R C Johnson
Journal:  Infect Immun       Date:  1988-02       Impact factor: 3.441

View more
  22 in total

1.  Detection of borreliacidal antibodies in Lyme borreliosis patient sera containing antimicrobial agents.

Authors:  D A Jobe; N Rawal; R F Schell; S M Callister
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

2.  Sensitivity and specificity of the borreliacidal-antibody test during early Lyme disease: a "gold standard"?

Authors:  S M Callister; D A Jobe; R F Schell; C S Pavia; S D Lovrich
Journal:  Clin Diagn Lab Immunol       Date:  1996-07

3.  A new animal model for studying Lyme disease spirochetes in a mammalian host-adapted state.

Authors:  D R Akins; K W Bourell; M J Caimano; M V Norgard; J D Radolf
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

4.  Reduced immune response to Borrelia burgdorferi in the absence of γδ T cells.

Authors:  Cuixia Shi; Bikash Sahay; Jennifer Q Russell; Karen A Fortner; Nicholas Hardin; Timothy J Sellati; Ralph C Budd
Journal:  Infect Immun       Date:  2011-07-18       Impact factor: 3.441

5.  Differentiation of borreliacidal activity caused by immune serum or antimicrobial agents by flow cytometry.

Authors:  Y F Liu; L C Lim; K Schell; S D Lovrich; S M Callister; R F Schell
Journal:  Clin Diagn Lab Immunol       Date:  1994-03

6.  Gamma interferon inhibits production of Anti-OspA borreliacidal antibody in vitro.

Authors:  Erik L Munson; Brian K Du Chateau; Jani R Jensen; Steven M Callister; David J DeCoster; Ronald F Schell
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

7.  The 39-kilodalton protein of Borrelia burgdorferi: a target for bactericidal human monoclonal antibodies.

Authors:  M Scriba; J S Ebrahim; T Schlott; H Eiffert
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

8.  Seroprotective groups among isolates of Borrelia burgdorferi.

Authors:  S D Lovrich; S M Callister; L C Lim; R F Schell
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

9.  Sera from OspA-vaccinated dogs, but not those from tick-infected dogs, inhibit in vitro growth of Borrelia burgdorferi.

Authors:  R K Straubinger; Y F Chang; R H Jacobson; M J Appel
Journal:  J Clin Microbiol       Date:  1995-10       Impact factor: 5.948

10.  Ability of the borreliacidal antibody test to confirm lyme disease in clinical practice.

Authors:  Steven M Callister; Dean A Jobe; William A Agger; Ronald F Schell; Todd J Kowalski; Steven D Lovrich; Jennifer A Marks
Journal:  Clin Diagn Lab Immunol       Date:  2002-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.